Praxis Precision Medicines shares were down 3.73% in Monday trading (April 27, 2026), extending a choppy tape after a strong April move that lifted the stock close to its highs. No fresh corporate announcement was evident Monday, leaving the decline consistent with a post-catalyst pullback rather than a new fundamental negative.

The most recent company-moving development was the FDA’s acceptance for review of Praxis’ New Drug Application for ulixacaltamide HCl in essential tremor, with a PDUFA target action date of January 29, 2027 and no advisory committee meeting expected. That regulatory step helped push the stock higher earlier in April, and Monday’s weakness fits a common pattern of traders locking in gains after a big headline-driven run. (investor.praxismedicines.com)

Near-term attention remains on the regulatory path for ulixacaltamide and the company’s broader late-stage pipeline, including relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies, which Praxis has also said it submitted for FDA review. Any updates on review timelines, labeling discussions, manufacturing readiness, or additional clinical readouts could quickly re-set sentiment given the stock’s volatility and large valuation swings. (investors.praxismedicines.com)

Praxis raised significant capital in early 2026, pricing an underwritten public offering at $260 per share for gross proceeds of about $575 million, which strengthened its balance sheet but can also increase sensitivity to profit-taking after rallies. The company has described funding that it expects to support operations into 2028, which reduces near-term financing risk even as investors debate how much success is already priced into the stock. (investors.praxismedicines.com)